[1] Zhang L,Wang F,Wang L,et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet,2012,379（9818）:815-822.
[2] Cai J,Fan X,Mou L,et al. Association of reduced renal function with hepatitis B virus infection and elevated alanine aminotransferase. Clin J Am Soc Nephrol,2012,7（10）:1561-1566.
[3] Chen YC. 13-year nationwide cohort study of chronic kidney disease risk among treatment-naive patients with chronic hepatitis B in Taiwan. BMC Nephrol,2015,16:110.
4] 陈香美, 孙雪峰, 蔡广研. 我国慢性肾脏病防治的公共健康政策思考. 中华医学杂志,2014.94（4）:241-243.
[5] 张路霞,左力,徐国宾,等. 北京市石景山地区中老年人群中慢性肾脏病的流行病学研究. 中华肾脏病杂志,2006,22:67-71．
[6] http://www.cfhpc.org/upload/ppt/20150525223338670.pdf.
[7] Fernandez-Fernandez B1,Montoya-Ferrer A,Sanz AB,et al. Tenofovir nephrotoxicity:2011 update. AIDS Res Treat,2011;2011:354908.
[8] Girgis CM,Wong T,Ngu MC,et al. Hypophosphataemic osteomalacia in patients on adefovir dipivoxil. J Clin Gastroenterol, 2011,45:468-473.
[9] Hall AM,Hendry BM,Nitsch D,et al. Tenofovir-associated kidney toxicity in HIV-infected patients:a review of the evidence. Am J Kidney Dis,2011,57:773-780.
[10] Gara N,Zhao X,Collins MT,et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther,2012,35（11）:1317-1325.
[11] Kim YJ,Cho HC,Sinn DH,et al. Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. J Gastroenterol Hepatol,2012,27（2）:306-312.
[12] Marcellin P GE,Flisiak R,Trinh H,et al. Long-term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8 year results from two phase 3 trials. Hepatology,2014,60:313A-314A.
[13] KDIGO.Chapter 1:Definition and classification of CKD. Kidney Int Suppl （2011）,2013,3（1）:19-62.
[14] 黎磊石. 中国肾脏病学. 人民军医出版社,2008:14-16.
[15] Chronic Kidney Disease Prognosis Consortium,Matsushita K,van der Velde M,et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts:a collaborative meta-analysis. Lancet,2010,375（9731）:2073-2081.
[16] Wen CP,Matsushita K,Coresh J,et al. Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar.Kidney Int,2014,86（4）:819-827.
[17] Shin JH,Kwon HJ,Jang HR,et al. Risk Factors for renal functional decline in chronic hepatitis B patients receiving oral antiviral agents.Medicine （Baltimore）,2016,95（1）:e2400.
[18] Wen CP,Matsushita K,Coresh J,et al. Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar. Kidney Int,2014,86（4）:819-827.
[19] Shin JH,Kwon HJ,Jang HR,et al. Risk factors for renal functional decline in chronic hepatitis B patients receiving oral antiviral agents. Medicine （Baltimore）,2016,95（1）:e2400.delete
[20] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2015年版）.实用肝脏病杂志,2016,19（3）：Ⅴ-ⅩⅩⅢ.
[21] Sarin SK,Kumar M,Lau GK,et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update. Hepatol Int,2016,10（1）:1-98.
[22] Wu X,Cai S,2,Li Z,et al. Potential effects of telbivudine and entecavir on renal function:a systematic review and meta-analysis. Virol J,2016,13（1）:64.
[23] Saadah OI,Sindi HH,Bin-Talib Y,et al. Entecavir treatment of children 2-16 years of age with chronic hepatitis B infection. Arab J Gastroenterol,2012,13:41-44.
[24] Jonas MM,Chang MH,Sokal E,et al. Randomized controlled trial of entecavir versus placebo in children with HBeAg-positive chronic hepatitis B. Hepatology,2015.doi:10.1002/hep.28015.
[25] Sun J,Xie Q,Tan D,et al. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients:a randomized,controlled study. Hepatology,2014,59:1283-1292.
[26 Liaw YF,Kao JH,Piratvisuth T,et al. Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2012 update. Hepatol Int,2012,6（3）:531-561.
[27] Qi X,Wang J,Chen L,et al. Impact of nucleos（t）ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B. Medicine （Baltimore）,2015,94（15）:e646.
[28] Qi X,Wang JY,Mao RC,et al. Impact of nucleos（t）ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B:a prospective cohort study in China. J Viral Hepat,2015,22（1）:46-54.
[29] 蔡建芳, 窦晓丽, 文煜冰, 等.乙型肝炎病毒相关性肾炎的相关因素分析. 中华肾脏病杂志,2011,27（2）:96-99.
[30] Lim YS,Larson TS,Benson JT,et al. Serum sodium, renal function,and survival of patients with end-stage liver disease. J Hepatol,2010,52（4）:523-528.
[31] WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization,2015 Mar[ahead of print].
[32 高宝秀,贺勇,李贵星,等. 慢性重型肝炎并发肝肾综合征的相关因素分析. 临床肝胆病杂志,2011,27（7）:749-751.
[33] Pipili C,Cholongitas E,Papatheodoridis G. Review article:nucleos（t）ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. Aliment Pharmacol Ther, 2014,39（1）:35-46.
[34] Lee S,Park JY,Song K,et al. Comparison of the effects of telbivudine and entecavir treatment on estimated glomerular filtration rate in patients with chronic hepatitis B. Gut Liver,2015 May 13[ahead of print].
[35] Chan HL,Chen YC,Gane EJ, et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat,2012,19（10）:732-743.
[36] Shouval D,Shibolet O. Immunosuppression and HBV reactivation. Semin Liver Dis,2013,33（2）,167-177.
[37] Mandalà M,Fagiuoli S,Francisci D,et al. Hepatitis B in immunosuppressed cancer patients:pathogenesis,incidence and prophylaxis. Crit Rev Oncol Hematol,2013,87（1）:12-27.
[38] Cholongitas E,Papatheodoridis GV. High genetic barrier nucleos（t）ide analogue（s） for prophylaxis from hepatitis B virus recurrence after liver transplantation:a systematic review. Am J Transplant,2013,13:353-362.
[39] Yi NJ,Choi JY,Suh KS,et al. Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin. J Gastroenterol,2013,48:1401-1410.
[40] Perrella A,Lanza AG,Pisaniello D,et al. Telbivudine prophylaxis for hepatitis B virus recurrence after liver transplantation improves renal function. Transplant Proc,2014,46（7）:2319-2321.
[41] Cholongitas E,Vasiliadis T,Goulis I,et al. Telbivudine is associated with improvement of renal function in patients transplanted for HBV liver disease. J Viral Hepat,2015,22（7）:574-580.
[42] Yap DY,Chan TM. The use of telbivudine in kidney transplant recipients with chronic hepatitis b virus infection-A preliminary experience. Nephrology （Carlton）,2015 Oct 20[ahead of print].
[43] European Association for the Study of the Liver. EASL Clinical Practice Guidelines:Liver transplantation. J Hepatol,2016,64（2）:433-485.
[44] 中华医学会肝病学分会肝癌学组. HBV/HCV相关性肝细胞癌抗病毒治疗专家建议. 中华实验和临床感染病杂志（电子版）,2012,6:651-655.
[45] Wu CY,Chen YJ,Ho HJ,et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA,2012,308:1906-1913.
[46] 中华人民共和国卫生部. 原发性肝癌诊疗规范（2011年版）摘要. 中华肝脏病杂志,2012,20:419-426.
[47] Sun P,Dong X,Cheng X,et al. Nucleot（s）ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment:a systematic review and meta-analysis. PLoS One,2014,9:e102761.
[48] Yin J,Li N,Han Y,et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus related hepatocellular carcinoma:a two-stage longitudinal clinical study. J Clin Oncol,2013,31:3647-3655.
[49] Kim YW,Kwon JH,Chung E,et al. Short term virologic efficacies of telbivudine versus entecavir against hepatitis B-related hepatocellular carcinoma. Gastroenterol Res Pract,2015,2015:181065.
[50] Gane EJ,Deray G,Liaw YF,et al. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology,2014,146:138-146,e5.
[51] Wang Y,Thongsawat S,Gane EJ,et al. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat,2013,20（4）:e37-46.
[52] European Association For The Study Of The Liver. EASL clinical practice guidelines:Management of chronic hepatitis B virus infection. J Hepatol,2012,57（1）:167-185. |
